Bayer AG NA (BAYN) - Net Assets
Based on the latest financial reports, Bayer AG NA (BAYN) has net assets worth €26.06 Billion EUR (≈ $30.47 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€110.61 Billion ≈ $129.31 Billion USD) and total liabilities (€84.54 Billion ≈ $98.84 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Bayer AG NA for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €26.06 Billion |
| % of Total Assets | 23.56% |
| Annual Growth Rate | 2.67% |
| 5-Year Change | -21.42% |
| 10-Year Change | -18.29% |
| Growth Volatility | 15.82 |
Bayer AG NA - Net Assets Trend (1998–2025)
This chart illustrates how Bayer AG NA's net assets have evolved over time, based on quarterly financial data. Check how tangible is Bayer AG NA's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Bayer AG NA (1998–2025)
The table below shows the annual net assets of Bayer AG NA from 1998 to 2025. For live valuation and market cap data, see Bayer AG NA (BAYN) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €26.06 Billion ≈ $30.47 Billion |
-18.67% |
| 2024-12-31 | €32.05 Billion ≈ $37.46 Billion |
-3.12% |
| 2023-12-31 | €33.08 Billion ≈ $38.67 Billion |
-15.02% |
| 2022-12-31 | €38.93 Billion ≈ $45.51 Billion |
+17.36% |
| 2021-12-31 | €33.17 Billion ≈ $38.78 Billion |
+8.04% |
| 2020-12-31 | €30.70 Billion ≈ $35.89 Billion |
-35.39% |
| 2019-12-31 | €47.52 Billion ≈ $55.55 Billion |
+2.97% |
| 2018-12-31 | €46.15 Billion ≈ $53.95 Billion |
+25.19% |
| 2017-12-31 | €36.86 Billion ≈ $43.09 Billion |
+15.56% |
| 2016-12-31 | €31.90 Billion ≈ $37.29 Billion |
+25.36% |
| 2015-12-31 | €25.45 Billion ≈ $29.75 Billion |
+25.85% |
| 2014-12-31 | €20.22 Billion ≈ $23.64 Billion |
-2.82% |
| 2013-12-31 | €20.80 Billion ≈ $24.32 Billion |
+12.04% |
| 2012-12-31 | €18.57 Billion ≈ $21.71 Billion |
-3.64% |
| 2011-12-31 | €19.27 Billion ≈ $22.53 Billion |
+1.98% |
| 2010-12-31 | €18.90 Billion ≈ $22.09 Billion |
-0.29% |
| 2009-12-31 | €18.95 Billion ≈ $22.16 Billion |
+15.98% |
| 2008-12-31 | €16.34 Billion ≈ $19.10 Billion |
-2.86% |
| 2007-12-31 | €16.82 Billion ≈ $19.67 Billion |
+30.89% |
| 2006-12-31 | €12.85 Billion ≈ $15.02 Billion |
+17.85% |
| 2005-12-31 | €10.90 Billion ≈ $12.75 Billion |
-11.84% |
| 2004-12-31 | €12.37 Billion ≈ $14.46 Billion |
+0.45% |
| 2003-12-31 | €12.31 Billion ≈ $14.40 Billion |
-20.39% |
| 2002-12-31 | €15.47 Billion ≈ $18.08 Billion |
-9.27% |
| 2001-12-31 | €17.05 Billion ≈ $19.93 Billion |
+3.82% |
| 2000-12-31 | €16.42 Billion ≈ $19.20 Billion |
+8.17% |
| 1999-12-31 | €15.18 Billion ≈ $17.75 Billion |
+18.80% |
| 1998-12-31 | €12.78 Billion ≈ $14.94 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bayer AG NA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €6.73 Billion | 25.92% |
| Common Stock | €2.52 Billion | 9.69% |
| Other Comprehensive Income | €-1.55 Billion | -5.99% |
| Other Components | €18.26 Billion | 70.38% |
| Total Equity | €25.95 Billion | 100.00% |
Bayer AG NA Competitors by Market Cap
The table below lists competitors of Bayer AG NA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vulcan Materials Company
NYSE:VMC
|
$36.49 Billion |
|
Powszechna Kasa Oszczednosci Bank Polski SA
WAR:PKO
|
$36.67 Billion |
|
AHOLD DELHAI.ADR16 EO-25
F:AHOD
|
$36.74 Billion |
|
Commerzbank AG
F:ZZMS
|
$36.76 Billion |
|
NTPC Limited
NSE:NTPC
|
$36.41 Billion |
|
China CSSC Holdings Ltd
SHG:600150
|
$36.41 Billion |
|
Prudential Financial Inc
NYSE:PRU
|
$36.40 Billion |
|
WEC Energy Group Inc
NYSE:WEC
|
$36.37 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bayer AG NA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 31,908,000,000 to 25,947,000,000, a change of -5,961,000,000 (-18.7%).
- Net loss of 3,620,000,000 reduced equity.
- Dividend payments of 127,000,000 reduced retained earnings.
- Share repurchases of 14,000,000 reduced equity.
- Other comprehensive income decreased equity by 21,081,000,000.
- Other factors increased equity by 18,881,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.62 Billion | -13.95% |
| Dividends Paid | €127.00 Million | -0.49% |
| Share Repurchases | €14.00 Million | -0.05% |
| Other Comprehensive Income | €-21.08 Billion | -81.25% |
| Other Changes | €18.88 Billion | +72.77% |
| Total Change | €- | -18.68% |
Book Value vs Market Value Analysis
This analysis compares Bayer AG NA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.74x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.68x to 1.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | €17.21 | €46.06 | x |
| 1999-12-31 | €20.54 | €46.06 | x |
| 2000-12-31 | €22.13 | €46.06 | x |
| 2001-12-31 | €23.22 | €46.06 | x |
| 2002-12-31 | €20.98 | €46.06 | x |
| 2003-12-31 | €18.05 | €46.06 | x |
| 2004-12-31 | €16.52 | €46.06 | x |
| 2005-12-31 | €14.58 | €46.06 | x |
| 2006-12-31 | €15.87 | €46.06 | x |
| 2007-12-31 | €19.99 | €46.06 | x |
| 2008-12-31 | €19.42 | €46.06 | x |
| 2009-12-31 | €22.51 | €46.06 | x |
| 2010-12-31 | €22.41 | €46.06 | x |
| 2011-12-31 | €22.86 | €46.06 | x |
| 2012-12-31 | €21.98 | €46.06 | x |
| 2013-12-31 | €24.66 | €46.06 | x |
| 2014-12-31 | €23.93 | €46.06 | x |
| 2015-12-31 | €28.88 | €46.06 | x |
| 2016-12-31 | €35.86 | €46.06 | x |
| 2017-12-31 | €41.53 | €46.06 | x |
| 2018-12-31 | €48.87 | €46.06 | x |
| 2019-12-31 | €48.22 | €46.06 | x |
| 2020-12-31 | €31.07 | €46.06 | x |
| 2021-12-31 | €33.61 | €46.06 | x |
| 2022-12-31 | €39.47 | €46.06 | x |
| 2023-12-31 | €33.52 | €46.06 | x |
| 2024-12-31 | €32.48 | €46.06 | x |
| 2025-12-31 | €26.41 | €46.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bayer AG NA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.94%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 4.26x
- Recent ROE (-13.95%) is below the historical average (6.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 12.84% | 5.75% | 0.96x | 2.34x | €357.20 Million |
| 1999 | 13.34% | 7.33% | 0.87x | 2.08x | €501.40 Million |
| 2000 | 10.29% | 5.63% | 0.81x | 2.26x | €46.74 Million |
| 2001 | 5.70% | 3.33% | 0.78x | 2.19x | €-728.63 Million |
| 2002 | 6.91% | 3.66% | 0.69x | 2.72x | €-474.20 Million |
| 2003 | -10.32% | -4.41% | 0.76x | 3.07x | €-2.48 Billion |
| 2004 | 6.13% | 3.23% | 0.62x | 3.08x | €-473.88 Million |
| 2005 | 12.71% | 5.57% | 0.67x | 3.39x | €293.59 Million |
| 2006 | 11.86% | 5.23% | 0.52x | 4.38x | €237.29 Million |
| 2007 | 13.75% | 7.11% | 0.63x | 3.07x | €627.60 Million |
| 2008 | 10.55% | 5.21% | 0.63x | 3.23x | €88.70 Million |
| 2009 | 7.19% | 4.36% | 0.61x | 2.70x | €-530.70 Million |
| 2010 | 6.91% | 3.71% | 0.68x | 2.73x | €-582.30 Million |
| 2011 | 12.86% | 6.76% | 0.69x | 2.75x | €548.80 Million |
| 2012 | 13.01% | 6.05% | 0.77x | 2.78x | €556.10 Million |
| 2013 | 15.39% | 7.94% | 0.78x | 2.48x | €1.12 Billion |
| 2014 | 17.04% | 8.29% | 0.59x | 3.49x | €1.42 Billion |
| 2015 | 16.94% | 8.92% | 0.62x | 3.05x | €1.68 Billion |
| 2016 | 14.94% | 12.97% | 0.42x | 2.71x | €1.50 Billion |
| 2017 | 19.93% | 20.95% | 0.47x | 2.04x | €3.66 Billion |
| 2018 | 3.69% | 4.61% | 0.29x | 2.75x | €-2.90 Billion |
| 2019 | 8.64% | 9.39% | 0.34x | 2.67x | €-642.70 Million |
| 2020 | -34.38% | -25.35% | 0.35x | 3.83x | €-13.55 Billion |
| 2021 | 3.03% | 2.27% | 0.37x | 3.64x | €-2.30 Billion |
| 2022 | 10.70% | 8.18% | 0.41x | 3.22x | €272.70 Million |
| 2023 | -8.93% | -6.17% | 0.41x | 3.53x | €-6.23 Billion |
| 2024 | -8.00% | -5.48% | 0.42x | 3.47x | €-5.74 Billion |
| 2025 | -13.95% | -7.94% | 0.41x | 4.26x | €-6.21 Billion |
Industry Comparison
This section compares Bayer AG NA's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $193,362,524,444
- Average return on equity (ROE) among peers: 28.35%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bayer AG NA (BAYN) | €26.06 Billion | 12.84% | 3.24x | $36.43 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $444.85 Million | -4.05% | 0.41x | $1.42 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $23.10 Billion | 22.34% | 0.30x | $10.04 Billion |
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | $33.87 Billion | 12.78% | 0.31x | $11.04 Billion |
| GRIFOLS ADR 1/2/EO-50 (G0F) | $8.61 Billion | 1.82% | 1.49x | $4.21 Billion |
| Grifols S.A (G0FB) | $3.73 Billion | 14.63% | 1.72x | $4.42 Billion |
| GSK PLC SP. ADR/2 NEW (GS70) | $10.10 Billion | 148.14% | 4.96x | $101.34 Billion |
| ORION CORP.B UNSP.ADR 1/2 (OFK0) | $1.28 Billion | 38.95% | 0.56x | $8.31 Billion |
| Sanofi (SNW2) | $63.15 Billion | 19.50% | 0.81x | $105.72 Billion |
| ASTELLAS PHARMA UNSP.ADR (YPHA) | $1.60 Trillion | 1.07% | 1.24x | $19.55 Billion |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; speci… Read more